文献速递消化道肿瘤与早癌消化内镜

45-49岁人群接受筛查性结肠镜检查的腺瘤检出率:基于GIQuIC登记分析

Adenoma Detection Rates in 45-49-Year-Old Persons Undergoing Screening Colonoscopy: Analysis From the GIQuIC Registry.
PubMed 文献 · Am J Gastroenterol · 2022-02-15

研究利用2014至2020年GIQuIC登记中45-75岁平均风险筛查性结肠镜检查数据,比较45-49岁、50-54岁和50-75岁人群的腺瘤检出率(ADR)。共纳入2,806,539例结肠镜检查,由814名内镜医师完成。45-49岁组平均ADR为28.6%,低于50-54岁组的31.8%(P < 0.001)和50-75岁组的36.3%(P < 0.001)。作者认为,随着45-49岁患者开始接受筛查性结肠镜检查的比例增高,内镜医师的ADR可能小幅下降。

要点

  • 45-49岁组平均ADR为28.6%,低于50-54岁组的31.8%(P < 0.001)。
  • 45-49岁组平均ADR为28.6%,低于50-75岁组的36.3%(P < 0.001)。
  • 作者认为45-49岁人群筛查比例增高后,内镜医师ADR可能小幅下降。

核心结论

  • 作者认为,随着45-49岁患者开始接受筛查性结肠镜检查的比例增高,内镜医师的腺瘤检出率可能小幅下降。

研究设计与样本

  • 研究使用2014至2020年提交至GI质量改进联盟(GIQuIC)登记的平均风险筛查性结肠镜检查数据,纳入45-75岁人群。
  • 共纳入2,806,539例筛查性结肠镜检查,由814名内镜医师完成。
  • 采用单因素方差分析(1-way ANOVA)比较45-49岁、50-54岁和50-75岁人群的腺瘤检出率差异。

主要发现

  • 45-49岁组平均腺瘤检出率为28.6%,50-54岁组为31.8%,两组比较P < 0.001。
  • 45-49岁组平均腺瘤检出率为28.6%,50-75岁组为36.3%,两组比较P < 0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The impact of lowering the colon cancer screening age from 50 to 45 years on the endoscopist adenoma detection rate (ADR) is not well studied. METHODS: We used average-risk screening colonoscopies submitted to the GI Quality Improvement Consortium registry from 2014 to 2020 among individuals aged 45-75 years. We used the 1-way ANOVA test to determine differences between ADRs among 45-49-year-old, 50-54-year-old, and 50-75-year-old individuals. RESULTS: A total of 2,806,539 screening colonoscopies were performed by 814 endoscopists. The mean ADR in the 45-49-year-old group was 28.6% compared with 31.8% for the 50-54-year-old group (P < 0.001) and 36.3% for the 50-75-year-old group (P < 0.001). DISCUSSION: Endoscopists might see a small drop in their ADR once a higher proportion of 45-49-year-old patients start undergoing screening colonoscopy.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bilal M, Holub J, Greenwald D, et al. Adenoma Detection Rates in 45-49-Year-Old Persons Undergoing Screening Colonoscopy: Analysis From the GIQuIC Registry. Am J Gastroenterol. 2022. PMID: 35169107. doi:10.14309/ajg.0000000000001684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。